Drugs / rebecsinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07250646 | May 2026 → Oct 2027 expected | acute myeloid leukemia, myelofibrosis | Aspera Biomedicines, Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rebecsinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07250646 ↗ |
| Action | Inhibit | “Inhibits ADAR1” NCT07250646 ↗ |
| Modality | Other / unclassified | “a Spliceosome Modulator That Inhibits ADAR1” NCT07250646 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT07250646 ↗ |
| Target | ADAR | “a Spliceosome Modulator That Inhibits ADAR1” NCT07250646 ↗ |